| scholarly article | Q13442814 |
| P2093 | author name string | Arndt Vogel | |
| Martha M Kirstein | |||
| P2860 | cites work | Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer | Q27027648 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis | Q27853129 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. | Q30855372 | ||
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study | Q33389870 | ||
| Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients | Q33809458 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology | Q50854464 | ||
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. | Q52861120 | ||
| FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer | Q53520406 | ||
| PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | Q58813317 | ||
| Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial | Q61867795 | ||
| Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study | Q83801480 | ||
| Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | Q34263478 | ||
| Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial | Q34344019 | ||
| Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer | Q34468886 | ||
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. | Q34492429 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial | Q34614245 | ||
| Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases | Q34650256 | ||
| Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial | Q34656044 | ||
| Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial | Q34656647 | ||
| Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). | Q34660081 | ||
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color | Q34660907 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Q34663697 | ||
| Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial | Q35599794 | ||
| Primary tumor location as a prognostic factor in metastatic colorectal cancer. | Q36047405 | ||
| Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis | Q36175906 | ||
| A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial | Q36451765 | ||
| Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer | Q37287501 | ||
| Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study | Q37481852 | ||
| Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. | Q38299712 | ||
| Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials | Q38386724 | ||
| First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). | Q38717058 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial | Q38940882 | ||
| Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. | Q40243706 | ||
| FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. | Q40601874 | ||
| Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study | Q42924532 | ||
| FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). | Q43649036 | ||
| PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer | Q46051180 | ||
| Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 | ||
| Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer | Q46742453 | ||
| Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. | Q47202956 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | colorectal cancer | Q188874 |
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 85-86 | |
| P577 | publication date | 2018-05-07 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Innovative Surgical Science | Q50817191 |
| P1476 | title | First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials | |
| P478 | volume | 3 |
Search more.